## Guidelines for psychiatrists for the treatment of alcohol use disorders

## **Reading and references:**

## Consensus guidelines:

Agabio R, Sinclair JM, Addolorato G, Aubin H-J, Beraha EM, Caputo F et al (2018) Baclofen for the treatment of alcohol use disorders: the Cagliari statement. *Lancet Psychiatry* 5 (12) 957-960

American Psychiatric Association (2018) Practice guideline for the pharmacological management of patients with alcohol use disorder *American Psychiatric Association* 

Haber P, Lintzeris N, Proude E and Lopatko O (2009) Guidelines for the treatment of alcohol problems. *Australian Government Department of Health and Ageing* 

Lingford-Hughes AR, Welch S, Peters L and Nutt DJ (2012) Evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from the British Association for Psychopharmacology. *Journal of Psychopharmacology* 26 899-952 <a href="https://www.bap.org.uk/pdfs/BAP">https://www.bap.org.uk/pdfs/BAP</a> Guidelines-Addiction.pdf

National Institute for Health and Care Excellence (NICE) UK (2011 – reviewed 2015) Alcohol use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence.

https://www.nice.org.uk/guidance/cg115

National Institute for Health and Care Excellence (NICE) UK (2010 updated 2017) Alcohol use disorders: diagnosis and management of physical complications.

https://www.nice.org.uk/guidance/cg100

National Institute for Health and Care Excellence (NICE) UK (2011) Co-existing severe mental illness (psychosis) and substance misuse: assessment and management in healthcare settings.

https://www.nice.org.uk/guidance/cg120

National Institute for Health and Care Excellence (NICE) UK (2016) Co-existing severe mental illness: community health and social care services. <a href="https://www.nice.org.uk/guidance/ng58">https://www.nice.org.uk/guidance/ng58</a>

Marel C, Mills KL et al (2016) Guidelines on the management of co-occurring alcohol and other drug and mental health conditions in alcohol and other drug treatment settings *Australian Government Department of Health* 

Public Health England (2017) Better care for people with co-occurring mental health and alcohol/drug use conditions. *PHE Publications* 

Royal College of Psychiatrists (with Royal College of Physicians and Royal College of General Practitioners) (2014) Alcohol and brain damage in adults *Royal College of Psychiatrists, London* 

## Other references:

Mann K et al (2018) Precision medicine in alcohol dependence: a controlled trial testing pharmacotherapy response among reward and relief drinking phenotypes. *Neuropsychopharmacology* **43** 891-899

Mann K et al (2013) Results of a double-blind placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study. *Addiction Biology* 18 (6) 937-946

Mark TL, Kassed CA, Vandivort-Warren R, et al: Alcohol and opioid dependence medications: prescription trends, overall and by physician specialty. *Drug Alcohol Depend* 99(1–3):345–349, 2009 18819759

Pettinati HM, Anton RF, Willenbring ML (2006) The COMBINE Study – an overview of the largest pharmacotherapy study to date for treating alcohol dependence *Psychiatry (Edgmont)* Oct (3) 36-39

Sinclair JM, Chambers SE, Shiles CJ and Baldwin DS (2016) Safety and tolerability of pharmacological treatment of alcohol dependence: comprehensive review of evidence. *Drug Safety* Jul 39(7) 627-45

Spithoff S (2017) First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario *Canadian Family Physician* 63(5) e277-e283

Woolf SH, Grol R, Hutchinson A, Eccles M, Grimshaw J (1999) Potential benefits, limitations and harms of clinical guidelines *British Medical Journal* 318 (7182) 527-530